Tummalapalli Sri Lekha, Mendu Mallika L, Struthers Sarah A, White David L, Bieber Scott D, Weiner Daniel E, Ibrahim Said A
Division of Healthcare Delivery Science & Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School.
Kidney Med. 2021 Jul 21;3(5):816-826.e1. doi: 10.1016/j.xkme.2021.06.006. eCollection 2021 Sep-Oct.
RATIONALE & OBJECTIVE: The Merit-Based Incentive Payment System (MIPS) is the largest quality payment program administered by the Centers for Medicare & Medicaid Services. Little is known about predictors of nephrologist performance in MIPS.
Cross-sectional analysis.
SETTING & PARTICIPANTS: Nephrologists participating in MIPS in performance year 2018.
Nephrologist characteristics: (1) participation type (individual, group, or MIPS alternative payment model [APM]), (2) practice size, (3) practice setting (rural, Health Professional Shortage Area [HPSA], or hospital based), and (4) geography (Census Division).
MIPS Final, Quality, Promoting Interoperability, Improvement Activities, and Cost scores. Using published consensus ratings, we also examined the validity of MIPS Quality measures selected by nephrologists.
Unadjusted and multivariable-adjusted linear regression models assessing the associations between nephrologist characteristics and MIPS Final scores.
Among 6,117 nephrologists participating in MIPS in 2018, the median MIPS Final score was 100 (interquartile range, 94-100). In multivariable-adjusted analyses, MIPS APM participation was associated with a 12.5-point (95% CI, 10.6-14.4) higher score compared with individual participation. Nephrologists in large (355-4,294 members) and medium (15-354 members) practices scored higher than those in small practices (1-14 members). In analyses adjusted for practice size, practice setting, and geography, among individual and group participants, HPSA nephrologists scored 1.9 (95% CI, -3.6 to -0.1) points lower than non-HPSA nephrologists, and hospital-based nephrologists scored 6.0 (95% CI, -8.3 to -3.7) points lower than non-hospital-based nephrologists. The most frequently reported quality measures by individual and group participants had medium to high validity and were relevant to nephrology care, whereas MIPS APM measures had little relevance to nephrology.
Lack of adjustment for patient characteristics.
MIPS APM participation, larger practice size, non-HPSA setting, and non-hospital-based setting were associated with higher MIPS scores among nephrologists. Our results inform strategies to improve MIPS program design and generate meaningful distinctions between practices that will drive improvements in care.
基于绩效的激励支付系统(MIPS)是医疗保险和医疗补助服务中心管理的最大规模的质量支付项目。对于MIPS中肾病专家表现的预测因素知之甚少。
横断面分析。
参与2018绩效年MIPS的肾病专家。
肾病专家特征:(1)参与类型(个人、团体或MIPS替代支付模式[APM]),(2)执业规模,(3)执业地点(农村、卫生专业人员短缺地区[HPSA]或医院),以及(4)地理位置(人口普查区)。
MIPS最终得分、质量得分、促进互操作性得分、改进活动得分和成本得分。使用已发表的共识评级,我们还检查了肾病专家选择的MIPS质量指标的有效性。
未调整和多变量调整的线性回归模型,评估肾病专家特征与MIPS最终得分之间的关联。
在2018年参与MIPS的6117名肾病专家中,MIPS最终得分的中位数为100(四分位间距,94 - 100)。在多变量调整分析中,与个人参与相比,参与MIPS APM与得分高出12.5分(95%CI,10.6 - 14.4)相关。大型(355 - 4294名成员)和中型(15 - 354名成员)执业的肾病专家得分高于小型执业(1 - 14名成员)的肾病专家。在根据执业规模、执业地点和地理位置进行调整的分析中,在个人和团体参与者中,HPSA的肾病专家得分比非HPSA的肾病专家低1.9分(95%CI, - 3.6至 - 0.1),医院执业的肾病专家得分比非医院执业的肾病专家低6.0分(95%CI, - 8.3至 - 3.7)。个人和团体参与者最常报告的质量指标具有中等至高有效性且与肾病护理相关,而MIPS APM指标与肾病相关性不大。
未对患者特征进行调整。
参与MIPS APM、较大的执业规模、非HPSA地点和非医院执业地点与肾病专家较高的MIPS得分相关。我们的结果为改进MIPS项目设计的策略提供了信息,并在不同执业之间产生有意义的差异,这将推动护理质量的提高。